Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AP306 at fixed doses for safety, tolerability, and efficacy in hyperphosphatemia associated with chronic kidney disease on hemodialysis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• AP306 (AP306)

Snippet

Sponsor: Alebund Pharmaceuticals | Conditions: Hyperphosphatemia, Chronic Kidney Disease Requiring Hemodialysis | Phase 2 | Status: NOT_YET_RECRUITING